secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-12-23T23:59:59+00:00
Accession:  0001193125-25-331113
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Bio sets CEO salary at $425K, SVP at $400K; retention bonuses tied to Feb 2026
--------------------------------------------------------------------------------

- Annual base salaries: Christopher Gerry $425,000, Josiah Craver $400,000, effective Nov 14, 2025.
- Each eligible for target annual bonus equal to 40% of base salary beginning FY 2026.
- First retention bonus equals full 2025 target bonus if employed through Feb 13, 2026 or terminated without cause.
- Second retention bonus is prorated 2026 target bonus if terminated without cause before 2026 bonus payment; 2x multiplier if not change-in-control.
- Severance benefits require execution of separation agreement and release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/0001193125-25-331113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525331113/d68669d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-331113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer